Biotinylated Human HLA-A*02:01&B2M&Vaccinia virus (YLAKLTALV) Complex Protein (Monomer, MALS verified)

Customer Reviews
Cat. No. / Size
Price
Qty
HLR-H82E8-25ug
$125.00
HLR-H82E8-200ug
$700.00
ETA of in-stock products:2 business days

Product Details

  • Synonyms

    HLA-A*0201 & B2M & Vaccinia virus (YLAKLTALV)

  • Source

    Biotinylated Human HLA-A*02:01&B2M&Vaccinia virus (YLAKLTALV) Complex Protein (HLR-H82E8) is expressed from human 293 cells (HEK293). It contains AA Gly 25 - Ile 308 (HLA-A*02:01) & Ile 21 - Met 119 (B2M) & YLAKLTALV peptide (Accession # AAA59606.1 (HLA-A*02:01) & P61769-1 (B2M) & YLAKLTALV).

    Predicted N-terminus: Gly 25 & Ile 21

    Request for sequence
  • Molecular Characterization

    Biotinylated Human HLA-A*02:01&B2M&Vaccinia virus (YLAKLTALV) Complex Protein is produced by co-expression of HLA and B2M loaded with Vaccinia virus peptide.

    This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

    The protein has a calculated MW of 36.3 kDa and 11.7 kDa. The protein migrates as 38-41 kDa and 10 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Labeling

    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

  • Purity

    >90% as determined by SDS-PAGE.

    >95% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • SDS-PAGE

    HLA-A*0201 & B2M & Vaccinia virus (YLAKLTALV) SDS-PAGE

    Biotinylated Human HLA-A*02:01&B2M&Vaccinia virus (YLAKLTALV) Complex Protein on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

  • SEC-MALS

    HLA-A*0201 & B2M & Vaccinia virus (YLAKLTALV) SEC-MALS

    The purity of Biotinylated Human HLA-A*02:01&B2M&Vaccinia virus (YLAKLTALV) Complex Protein (Cat. No. HLR-H82E8) is more than 95% and the molecular weight of this protein is around 45-60 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     HLA-A*0201 & B2M & Vaccinia virus (YLAKLTALV) ELISA

    Immobilized Biotinylated Human HLA-A0201 & B2M & Vaccinia virus (YLAKLTALV) Complex Protein (Cat. No. HLR-H82E8) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-HLA class I Antibody, Human IgG1 (W6/32) with a linear range of 0.1-1 ng/mL (QC tested).

    Protocol
  •  HLA-A*0201 & B2M & Vaccinia virus (YLAKLTALV) ELISA

    Immobilized Biotinylated Human HLA-A0201 & B2M & Vaccinia virus (YLAKLTALV) Complex Protein (Cat. No. HLR-H82E8) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-B2M Antibody, Human IgG1 with a linear range of 0.1-1 ng/mL (Routinely tested).

    Protocol

Customer Reviews
Writing Reviews

Background

Among the nonvirion proteins of the vaccinia virus (VACV), a 94-kDa long protein is most abundantly present; the protein is a truncated form of the 150-kDa A-type inclusion (ATI) protein of the cowpox virus encoded by the ati gene. This VACV protein does not form intracellular ATIs, being as it is a major immunogen upon infection/immunization of humans or animals with the VACV. variants demonstrated that the mutant LIVPΔati elicits a stronger protective response compared to the parent LIVP. The human HLA-A*0201 Vaccinia virus G5R (YLAKLTALV) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M, and YLAKLTALV peptide of the vaccinia virus.

Recent Advances

 
Contact Us
Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • Background
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland